<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01430039</url>
  </required_header>
  <id_info>
    <org_study_id>03.09.11.01</org_study_id>
    <secondary_id>31.08.11</secondary_id>
    <nct_id>NCT01430039</nct_id>
  </id_info>
  <brief_title>Syndecan-1 a Surrogate Marker for IBD</brief_title>
  <acronym>syndecan1</acronym>
  <official_title>Syndecan-1 as a Surrogate Marker for Inflammatory Bowel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meir Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meir Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Syndecan-1 is a protein on the surface intestinal cells. previous studies proved low levels
      of mucosal syndecan-1 levels on the surface of intestinal cells is patients with acute and
      chronic inflammation due to inflammatory bowel disease.

      this protein might shed from cell surface to the serum. The investigators wish to prove that
      elevated serum levels of syndecan-1 may be predictive of disease presence, extent and
      severity, that buy taking a simple blood sample from patients diagnosed with inflammatory
      bowel disease and comparing to normal subjects and to other markers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One of the main hypothesis for the etiology of Inflammatory bowel disease (IBD) is an
      inappropriate and ongoing activation of the mucosal immune system in response to the presence
      of normal luminal flora. This aberrant response is most likely facilitated by defects in both
      the barrier function and the mucosal immune system of the intestinal epithelium. Syndecans
      are a class proteoglycans that take part in both cell adhesion and growth factor binding. Of
      the four known syndecan core proteins, syndecan-1 (CD138) and one of the best studied of this
      group and is also the relevant to the this study as it is expressed on the basolateral
      surface of columnar epithelial cells of the colon. Syndecan-1 functions as an integral
      membrane protein that participates in cell proliferation, cell migration and cell matrix
      interactions in the GI tract. Evidence for a reduction of syndecan-1 expression in the
      regenerating epithelium that overlies inflamed tissue was reported in both acute and chronic
      inflammation. This protein that is lost from the inflamed mucosal membrane might shed to the
      serum. Elevated serum levels of syndecan-1 may be predictive of disease presence and extent.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Elevated serum syndecan-1 levels as a bio marker for IBD</measure>
    <time_frame>one year</time_frame>
    <description>elevated serum syndecan-1 levels in patients with IBD compared to control</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum syndecan-1 levels and disease severity Crohn's</measure>
    <time_frame>one year</time_frame>
    <description>Relationship between clinical data CDAI in crohn's patients and serum syndecan-1 levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum syndecan-1 levels and disease severity ulcerative colitis</measure>
    <time_frame>one year</time_frame>
    <description>Relationship between clinical data UCAI ulcerative colitis patients and serum syndecan-1 levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum syndecan-1 levels and C reactive protein(CRP) Crohn's</measure>
    <time_frame>one year</time_frame>
    <description>Relationship between lab data CRP levels in crohn's patients and serum syndecan-1 levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum syndecan-1 levels and C reactive protein(CRP) ulcerative colitis</measure>
    <time_frame>one year</time_frame>
    <description>Relationship between serum CRP levels and serum syndecan-1 levels in patients with ulcerative colitis</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">42</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <arm_group>
    <arm_group_label>Crohn's, ulcerative colitis</arm_group_label>
    <description>Patients with diagnosed with Crohn's disease or ulcerative colitis who agreed to participate in the study and singed informed consent and answered a Crohn's disease activity index questioner for Crohn's disease or the ulcerative colitis activity index questioner for ulcerative colitis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No disease</arm_group_label>
    <description>Healthy subjects with no known inflammatory disease. For basal serum levels of syndecan 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>Blood sample from a peripheral vein, 10ml total for blood count, total serum : protein, albumin, LDH, C-reactive protein,syndecan-1</description>
    <arm_group_label>No disease</arm_group_label>
    <other_name>Syndecan-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sample - venous blood 10 ml.</intervention_name>
    <description>venous blood sample from a peripheral vein, 10ml total for blood count, total serum : protein, albumin, LDH, C-reactive protein,syndecan-1</description>
    <arm_group_label>Crohn's, ulcerative colitis</arm_group_label>
    <other_name>Syndecan-1</other_name>
  </intervention>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      Venous blood sample for syndecan-1 levels, blood count, CRP levels,serum albumin and total
      protein
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Normal population, having no known inflammatory disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  informed consent

          -  no other concurrent inflammatory disease

          -  formal diagnosis of inflammatory bowel disease i.e Crohn's disease, Ulcerative colitis

        Exclusion Criteria:

          -  pregnancy

          -  fever at time of sample taking
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Assaf Stein, Md</last_name>
    <role>Principal Investigator</role>
    <affiliation>resident</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Yablecovitch D, Shabat-Simon M, Aharoni R, Eilam R, Brenner O, Arnon R. Beneficial effect of glatiramer acetate treatment on syndecan-1 expression in dextran sodium sulfate colitis. J Pharmacol Exp Ther. 2011 May;337(2):391-9. doi: 10.1124/jpet.110.174276. Epub 2011 Feb 10.</citation>
    <PMID>21310817</PMID>
  </reference>
  <reference>
    <citation>Bartlett AH, Hayashida K, Park PW. Molecular and cellular mechanisms of syndecans in tissue injury and inflammation. Mol Cells. 2007 Oct 31;24(2):153-66. Review.</citation>
    <PMID>17978567</PMID>
  </reference>
  <reference>
    <citation>Bode L, Salvestrini C, Park PW, Li JP, Esko JD, Yamaguchi Y, Murch S, Freeze HH. Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function. J Clin Invest. 2008 Jan;118(1):229-38.</citation>
    <PMID>18064305</PMID>
  </reference>
  <reference>
    <citation>Carey DJ. Syndecans: multifunctional cell-surface co-receptors. Biochem J. 1997 Oct 1;327 ( Pt 1):1-16. Review.</citation>
    <PMID>9355727</PMID>
  </reference>
  <reference>
    <citation>Seidel C, Sundan A, Hjorth M, Turesson I, Dahl IM, Abildgaard N, Waage A, Borset M. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood. 2000 Jan 15;95(2):388-92. Erratum in: Blood 2000 Apr 1;95(7):2197.</citation>
    <PMID>10627439</PMID>
  </reference>
  <reference>
    <citation>Principi M, Day R, Marangi S, Burattini O, De Francesco V, Ingrosso M, Pisani A, Panella C, Forbes A, Di Leo A, Francavilla A, Ierardi E. Differential immunohistochemical expression of syndecan-1 and tumor necrosis factor alpha in colonic mucosa of patients with Crohn's disease. Immunopharmacol Immunotoxicol. 2006;28(2):185-95.</citation>
    <PMID>16873088</PMID>
  </reference>
  <reference>
    <citation>Götte M. Syndecans in inflammation. FASEB J. 2003 Apr;17(6):575-91. Review.</citation>
    <PMID>12665470</PMID>
  </reference>
  <reference>
    <citation>Gaffney PR, O'Leary JJ, Doyle CT, Gaffney A, Hogan J, Smew F, Annis P. Response to heparin in patients with ulcerative colitis. Lancet. 1991 Jan 26;337(8735):238-9.</citation>
    <PMID>1670865</PMID>
  </reference>
  <reference>
    <citation>Day RM, Mitchell TJ, Knight SC, Forbes A. Regulation of epithelial syndecan-1 expression by inflammatory cytokines. Cytokine. 2003 Mar 7;21(5):224-33.</citation>
    <PMID>12824007</PMID>
  </reference>
  <reference>
    <citation>Day R, Ilyas M, Daszak P, Talbot I, Forbes A. Expression of syndecan-1 in inflammatory bowel disease and a possible mechanism of heparin therapy. Dig Dis Sci. 1999 Dec;44(12):2508-15.</citation>
    <PMID>10630505</PMID>
  </reference>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2011</study_first_submitted>
  <study_first_submitted_qc>September 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2011</study_first_posted>
  <last_update_submitted>April 7, 2015</last_update_submitted>
  <last_update_submitted_qc>April 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn's disease</keyword>
  <keyword>ulcerative colitis</keyword>
  <keyword>Syndecan-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

